PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
GlaxoSmithKline plc (GSK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US37733W1053

CUSIP

37733W105

Sector

Healthcare

IPO Date

Jul 9, 1986

Highlights

Market Cap

$69.84B

EPS (TTM)

$1.54

PE Ratio

22.23

PEG Ratio

0.76

Total Revenue (TTM)

$31.27B

Gross Profit (TTM)

$22.46B

EBITDA (TTM)

$7.73B

Year Range

$32.83 - $44.85

Target Price

$45.07

Short %

0.95%

Short Ratio

2.50

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
GSK vs. PFE GSK vs. NVS GSK vs. SHEL GSK vs. NGG GSK vs. WBA GSK vs. ^GSPC GSK vs. MAIN GSK vs. RXRX GSK vs. VTI GSK vs. SCHD
Popular comparisons:
GSK vs. PFE GSK vs. NVS GSK vs. SHEL GSK vs. NGG GSK vs. WBA GSK vs. ^GSPC GSK vs. MAIN GSK vs. RXRX GSK vs. VTI GSK vs. SCHD

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in GlaxoSmithKline plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


1,800.00%1,900.00%2,000.00%2,100.00%2,200.00%2,300.00%2,400.00%JulyAugustSeptemberOctoberNovemberDecember
1,831.99%
2,318.32%
GSK (GlaxoSmithKline plc)
Benchmark (^GSPC)

Returns By Period

GlaxoSmithKline plc had a return of -5.50% year-to-date (YTD) and -4.05% in the last 12 months. Over the past 10 years, GlaxoSmithKline plc had an annualized return of 2.32%, while the S&P 500 had an annualized return of 11.01%, indicating that GlaxoSmithKline plc did not perform as well as the benchmark.


GSK

YTD

-5.50%

1M

0.00%

6M

-16.00%

1Y

-4.05%

5Y*

-2.62%

10Y*

2.32%

^GSPC (Benchmark)

YTD

23.11%

1M

-0.36%

6M

7.02%

1Y

23.15%

5Y*

12.80%

10Y*

11.01%

Monthly Returns

The table below presents the monthly returns of GSK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20246.42%7.28%2.31%-3.34%8.93%-14.00%0.70%14.32%-6.90%-10.08%-6.09%-5.50%
20230.34%-1.87%3.82%1.26%-5.84%6.07%-0.20%-0.21%3.19%-1.52%1.82%2.97%9.71%
20221.63%-5.26%4.06%3.95%-2.28%-0.84%-4.84%-22.10%-9.39%12.71%5.30%1.59%-18.27%
20211.22%-8.19%6.19%4.62%5.22%2.71%0.80%2.76%-6.21%10.78%-1.67%7.25%26.63%
2020-0.40%-12.21%-6.51%11.03%0.74%-2.70%-1.15%-0.65%-4.95%-11.21%11.48%0.03%-17.78%
20192.59%4.44%3.54%-1.58%-4.89%3.57%3.15%1.87%2.65%7.31%0.38%3.32%29.12%
20185.75%-1.54%7.60%2.66%2.35%-0.52%3.18%-1.46%-0.81%-2.76%8.47%-8.74%13.68%
20172.08%6.97%1.64%-2.99%9.39%-2.51%-6.03%0.50%0.92%-10.27%-2.44%1.17%-3.07%
20162.33%-3.41%4.86%5.82%0.01%2.29%3.99%-2.50%-0.76%-7.23%-4.46%1.91%1.97%
20152.95%9.34%-2.68%-0.00%-2.64%-6.13%4.30%-4.54%-6.06%11.99%-4.61%-0.40%-0.36%
2014-3.47%9.97%-4.49%3.63%-1.47%-0.85%-9.56%2.85%-6.37%-1.04%3.48%-7.99%-15.76%
20134.92%-2.02%6.54%10.08%1.32%-3.48%1.98%0.92%-1.41%4.90%1.73%0.89%28.81%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of GSK is 35, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of GSK is 3535
Overall Rank
The Sharpe Ratio Rank of GSK is 3737
Sharpe Ratio Rank
The Sortino Ratio Rank of GSK is 3030
Sortino Ratio Rank
The Omega Ratio Rank of GSK is 3030
Omega Ratio Rank
The Calmar Ratio Rank of GSK is 3838
Calmar Ratio Rank
The Martin Ratio Rank of GSK is 4040
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for GSK, currently valued at -0.18, compared to the broader market-4.00-2.000.002.00-0.181.90
The chart of Sortino ratio for GSK, currently valued at -0.10, compared to the broader market-4.00-2.000.002.004.00-0.102.54
The chart of Omega ratio for GSK, currently valued at 0.99, compared to the broader market0.501.001.502.000.991.35
The chart of Calmar ratio for GSK, currently valued at -0.15, compared to the broader market0.002.004.006.00-0.152.81
The chart of Martin ratio for GSK, currently valued at -0.34, compared to the broader market0.0010.0020.00-0.3412.39
GSK
^GSPC

The current GlaxoSmithKline plc Sharpe ratio is -0.18. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of GlaxoSmithKline plc with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.00JulyAugustSeptemberOctoberNovemberDecember
-0.18
1.90
GSK (GlaxoSmithKline plc)
Benchmark (^GSPC)

Dividends

Dividend History

GlaxoSmithKline plc provided a 4.62% dividend yield over the last twelve months, with an annual payout of $1.56 per share.


4.00%5.00%6.00%7.00%$0.00$0.50$1.00$1.50$2.00$2.5020132014201520162017201820192020202120222023
Dividends
Dividend Yield
PeriodTTM20232022202120202019201820172016201520142013
Dividend$1.56$1.39$1.68$2.21$2.06$2.05$2.16$2.06$2.77$2.45$2.65$2.41

Dividend yield

4.62%3.75%4.78%4.92%5.49%4.28%5.55%5.72%7.06%5.96%6.09%4.43%

Monthly Dividends

The table displays the monthly dividend distributions for GlaxoSmithKline plc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024$0.00$0.41$0.00$0.00$0.38$0.00$0.00$0.39$0.00$0.00$0.39$0.00$1.56
2023$0.00$0.34$0.00$0.00$0.35$0.00$0.00$0.36$0.00$0.00$0.34$0.00$1.39
2022$0.00$0.62$0.00$0.00$0.35$0.00$0.00$0.39$0.00$0.00$0.32$0.00$1.68
2021$0.00$0.63$0.00$0.00$0.53$0.00$0.00$0.53$0.00$0.00$0.52$0.00$2.21
2020$0.00$0.60$0.00$0.00$0.47$0.00$0.00$0.49$0.00$0.00$0.50$0.00$2.06
2019$0.00$0.60$0.00$0.00$0.50$0.00$0.00$0.46$0.00$0.00$0.49$0.00$2.05
2018$0.00$0.64$0.00$0.00$0.53$0.00$0.00$0.50$0.00$0.00$0.49$0.00$2.16
2017$0.00$0.58$0.00$0.00$0.49$0.00$0.00$0.50$0.00$0.00$0.50$0.00$2.06
2016$0.00$1.25$0.00$0.00$0.55$0.00$0.00$0.50$0.00$0.00$0.46$0.00$2.77
2015$0.00$0.70$0.00$0.00$0.58$0.00$0.00$0.59$0.00$0.00$0.58$0.00$2.45
2014$0.00$0.75$0.00$0.00$0.64$0.00$0.00$0.65$0.00$0.00$0.61$0.00$2.65
2013$0.69$0.00$0.00$0.55$0.00$0.00$0.55$0.00$0.00$0.62$0.00$2.41

Dividend Yield & Payout


Dividend Yield
5.0%10.0%15.0%20.0%4.6%
GlaxoSmithKline plc has a dividend yield of 4.62%, which is quite average when compared to the overall market.
Payout Ratio
200.0%400.0%600.0%800.0%37.4%
GlaxoSmithKline plc has a payout ratio of 37.41%, which is quite average when compared to the overall market. This suggests that GlaxoSmithKline plc strikes a balance between reinvesting profits for growth and paying dividends to shareholders.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-25.00%-20.00%-15.00%-10.00%-5.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-24.87%
-3.58%
GSK (GlaxoSmithKline plc)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the GlaxoSmithKline plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the GlaxoSmithKline plc was 55.21%, occurring on Aug 13, 1993. Recovery took 765 trading sessions.

The current GlaxoSmithKline plc drawdown is 24.87%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-55.21%Jan 10, 1992404Aug 13, 1993765Aug 22, 19961169
-51.99%Jan 7, 1999889Jul 23, 20021190Apr 16, 20072079
-49.7%Apr 23, 2007474Mar 9, 2009785Apr 18, 20121259
-46.08%Jul 17, 1987282Aug 25, 1988454Jun 13, 1990736
-38.74%Apr 14, 2022114Sep 27, 2022404May 7, 2024518

Volatility

Volatility Chart

The current GlaxoSmithKline plc volatility is 6.76%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%JulyAugustSeptemberOctoberNovemberDecember
6.76%
3.64%
GSK (GlaxoSmithKline plc)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of GlaxoSmithKline plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an assessment of the market value of GlaxoSmithKline plc compared to its peers in the Drug Manufacturers - General industry.


PE Ratio
200.0400.0600.0800.01,000.022.2
The chart displays the price to earnings (P/E) ratio for GSK in comparison to other companies of the Drug Manufacturers - General industry. Currently, GSK has a PE value of 22.2. This PE ratio falls in the average range for the industry.
PEG Ratio
10.020.030.00.8
The chart displays the price to earnings to growth (PEG) ratio for GSK in comparison to other companies of the Drug Manufacturers - General industry. Currently, GSK has a PEG value of 0.8. This PEG ratio falls in the average range for the industry.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for GlaxoSmithKline plc.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab